Peter Dritschilo
Presidente presso SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Patrimonio netto: 3 483 $ in data 31/05/2024
Profilo
Peter Dritschilo currently works at Shuttle Pharmaceuticals, Inc., as President & Chief Operating Officer from 2012 and Shuttle Pharmaceuticals Holdings, Inc., as President & Chief Operating Officer.
Mr. Dritschilo received his undergraduate degree from Georgetown University and Masters Business Admin degree from The GW School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 21/03/2024 | 6 560 ( 0.04% ) | 3 483 $ | 31/05/2024 |
Posizioni attive di Peter Dritschilo
| Società | Posizione | Inizio |
|---|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Presidente | 18/12/2012 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Presidente | 01/12/2012 |
Formazione di Peter Dritschilo
| Georgetown University | Undergraduate Degree |
| The GW School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
- Borsa valori
- Insiders
- Peter Dritschilo
